132606-95-2

Basic information

• Product Name: (2R,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert-butyldimethylsilyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate
• Synonyms: (2R,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert-butyldimethylsilyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate
• CAS NO: 132606-95-2
• Molecular Weight: 851.968
• Mol File: 132606-95-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (2R,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert-butyldimethylsilyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert-butyldimethylsilyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate(132606-95-2)
• EPA Substance Registry System: (2R,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert-butyldimethylsilyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate(132606-95-2)

Safety Data

• Hazardous Substances Data: 132606-95-2(Hazardous Substances Data)

Upstream product

• 104992-55-4 N⁶-benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-(tert-butyldimethylsilyl)adenosine 3'-O-(2-cyanoethyl N,N-diisopropylphosphoramidite) 

Downstream Products

• 917480-85-4 C₁₀H₁₃N₅O₄SiC₆H₁₄PO₃HC(C₆H₅)3C₁₁H₁₁O₂ 
• 160056-44-0 C₁₀H₁₃N₅O₄SiC₆H₁₄PO₃HC(C₆H₅)3C₂H₃O₂C₇H₄C₆H₄ 
• 911848-61-8 C₁₀H₁₃N₅O₄SiC₆H₁₄PO₃HC(C₆H₅)3C₂H₃O₂C₇H₄C₆H₃Cl 
• 911848-45-8 C₁₀H₁₃N₅O₄SiC₆H₁₄PO₃HC(C₆H₅)3C₂H₃O₂C₇H₄OC₆H₃NO 
• 960148-65-6 C₁₀H₁₃N₅O₄SiC₆H₁₄PO₃HC(C₆H₅)3C₂H₃O₂C₇H₄OC₅H₈ 

Relevant articles and documents

Chemical synthesis, purification, and characterization of 3′-5′-linked canonical cyclic dinucleotides (CDNs)

So far, four cyclic dinucleotides (CDNs) have been discovered as important second messengers in nature, where three canonical CDNs of c-di-GMP, c-di-AMP and c-AMP-GMP were found in bacteria containing two 3′-5′ phosphodiester linkages and one non-canonica

DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS

Provided herein are immunoconjugates comprising an anti-DC-SiGN antibody conjugated to a STING agonist. Also disclosed are methods of making the immunoconjugates and methods of treating cancer using the immunoconjugates.

Synthesis of All Possible Canonical (3′-5′-Linked) Cyclic Dinucleotides and Evaluation of Riboswitch Interactions and Immune-Stimulatory Effects

The cyclic dinucleotides (CDNs) c-di-GMP, c-di-AMP, and c-AMP-GMP are widely utilized as second messengers in bacteria, where they signal lifestyle changes such as motility and biofilm formation, cell wall and membrane homeostasis, virulence, and exo-elec